Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Enhancin[Co-amoxiclav] Versus Postoperative Enhancin in Prevention of Postadenotonsillectomy Morbidity.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients below 12year scheduled to undergo adenotonsillectomy whose parents or guardians give consent for recruitment into the study.~Exclusion Criteria:~* Non consenting parents or guardians. Antibiotic use in the week preceding surgery. Patients with co mordities. Known allergies to Co-amoxiclav. Patients who develop complication that warrant change of antibiotic.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Intravenous intraoperative Enhancin (Type: EXPERIMENTAL): Patients received a dose of intravenous Enhancin at induction and only oral Paracetamol in the postoperative period.
- Postoperative oral Enhancin. (Type: ACTIVE_COMPARATOR): Patients received postoperative oral Enhancin for five days in addition to oral Paracetamol for the same duration. They did not receive an antibiotic during the operation.

Based on this trial design, predict the completion outcome and termination type (if applicable).